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Purpose/Objective: To evaluate the first clinical and dosimetry data 
of a new afterloading machine using a Co-60 source. 
Materials and Methods: Patients with prostate cancer were treated 
by combined external beam radiotherapy (EBRT) followed by a 
brachytherapy boost: After 46Gy EBRT to the prostate two fractions of 
9 Gy were applied, each 2 weeks apart. In 2008 a new afterloading 
machine (Multisource®, Eckert & Ziegler BEBIG, Germany) was 
installed using a Co-60 source. Toxicity data were compared to a 
cohort of 131 patients treated with Ir-192 and the same fractionation 
scheme at our institution from 2001 – 2008. 
Results: A total of 117 patientswere treated with Co-60 from 01/2008-
10/2012. Median age at diagnosis was 72 years. Patients had a mean 
PSA value of 25.5 ng/ml and a mean Gleason-score of 7.2 (< 6: 16%, 7: 
65%, > 8: 19%). High risk tumours were present in 53%, intermediate 
risk in 42% and low risk in 5% of the patients. Neo-/adjuvant 
antihormonal therapy was given in 38.2%. Mean prostate volume was 
31.7ml and mean IPSS was 7.4 at presentation. DVH parameters (mean 
values) for brachytherapy were D90: 8.97 Gy, COIN: 0.68. Dmax for 
rectal wall was 8.0 Gy and 11.8 Gy for the urethra. The TRAK value 
was 0.27 cGy x m2. Toxicities were evaluated according to CTCAE 
v3.0. Most frequent acute GU toxicities were an increase in urinary 
frequency (49%, 19.6% and 5.9%, grade I / II / III), painful voiding 
(45%, 4% and 4%, grade I / II / III) and urinary bleeding after 
interstitial brachytherapy (36.5% and 11.5%, grade I / II). Acute GI 
toxicity presented with proctitis (12% and 6%, grade I / II) and 
diarrhea (14% grade I). No acute grade IV toxicity was reported. Late 
toxicities are not presented because of the short follow-up (median 
13.7 months). In comparison with the patients formerly treated with 
Ir-192 no significant increase in acute adverse events were reported 
(39.2% vs. 29.8% for grade II and 9.8% vs. 5.3% for grade III, Co-60 vs. 
Ir-192). The comparison of the dosimetry data is still under evaluation 
and will be presented at the meeting. 
Conclusions: Using Co-60 for a HDR-brachytherapy boost after EBRT is 
a feasible technique in prostate cancer patients with no excess of 
toxicities in regard to Ir-192. Due to the short follow-up long term 
data on clinical outcome have to be awaited.  
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Purpose/Objective: The standard for the determination of post-
implant dose parameters of trans rectal ultrasound-guided permanent 
radioactive I-125 implantation of the prostate (BT) is a CT-based 
identification of the implanted seeds and of the prostate and organs 
at risk. However, while CT depicts the seeds very clearly, the contour 
of the prostate cannot reliably be identified, due to poor soft tissue 
contrast.In this study, we evaluated added use of T2-weighted MR 
images (MRI) for prostate delineation, while the CT were used for 
seed identification.  
Materials and Methods: Thirteen patients underwent both CT and MRI 
30 days after BT. CT and MRI were manually registered based on seed 
localization using the registration tool in Eclipse V8.9. Registration 
was performed independently by 2 physicists. One physician contoured 
the prostate on CT and MRI on different days without seeing the other 
image modality. The evaluation was based on the minimum dose to 90 
percent of the prostate (D90) and the percentage of the prostate 
receiving 100 percent of the prescribed dose (V100).The D90 and V100 
were computed for CT-based (CT was used for seed localization and 
prostate delineation) and for CT/MRI based postplanning (CT was used 
for seed localization and MRI for prostate delineation). The variability 
of the dosimetric parameters based on registration uncertainty was 
estimated based on the variation of the D90 and V100 between the 2 
physicists performing the registration. 
Results: In contrast to other reports, we found a sufficient seed 
visibility on MRI for an effective registration based on seed 
localization. The major difficulty during registration was that the 
prostate shape varied in some cases and consequently not all seeds 
could be matched. This created an uncertainty for the registration, 
and depending on which seed group was chosen to match, the 2 
physicists arrived at different registrations. Eliminating the 2 patients 
for which the registration was not possible, we found that the mean 
difference in the D90 and V100 between the CT-based and the 
CT/MRI-based post-planning was 4% and 9% (max deviation -18% and 
30%) respectively. The mean difference in the D90 and V100 between 
the CT/MRI based post-planning by the 2 physicists (registration 
uncertainty) was 3% and 2% (max value 10% and 5%) respectively. 
Conclusions: MRI is valuable in contouring more precisely the prostate 
and therefore getting a more realistic dosimetric characterization of 
the implantation. However, the registration adds an uncertainty to 
the postplanning process and this uncertainty must be understood to 
obtain meaningful data. We found that it is important to be critical 
during the registration and to perform a CT/MRI based postplanning 
only for those patients for which we feel an optimal registration can 
be performed. Our preliminary findings show that if this is done, there 
is a gain in post-planning dosimetric accuracy. Future investigations 
will evaluate the use of 3D MRI images to see if the uncertainty on the 
CT/MRI registration can be further reduced. 
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Purpose/Objective: The nonmelanoma skin cancers are among the 
most common tumours, especially in older patients. The classic 
approach is surgery, but the development experienced by high dose 
rate brachytherapy, achieves similar cure rates and cosmetic results. 
With this approach, at the Hospital La Fe, the Valencia Applicators are 
used as accessories of the Nucletron HDR microSelectron Unit, which 
allow treatment of lesions up to 4 mm deep and 3 cm in maximum 
diameter. The purpose of this work was to assess the oncologic and 
cosmetic results, and acute toxicity (RTOG/CTCv3), in patients with 
nonmelanoma skin carcinoma treated with Valencia Applicator with a 
new regime of hypofractionation. 
Materials and Methods: We retrospectively reviewed the results of 48 
basal cell carcinomas in 33 patients treated at our institution between 
January 2008 and March 2010, with a follow-up between 24 and 54 
months (30% of the patients with a follow-up longer than 3 years). 
Most of the patients (55%) were male, and 70% were over 70 years. 
The treatment protocol includes the determination of the area (GTV-
CTV) by a dermatologist with the dermatoscope and depth ultrasound. 
The treatment schedule consists of 7 Gy delivered in 6 by 7 Gy or 7 by 
6 Gy fractions, scheduled in 2 sessions per week, reaching 42 Gy . The 
treatment is prescribed at 3 mm depth in those lesions whose depth is 
3 mm or less, and at 4 mm to lesions between 3 mm and 4 mm. 
Results: Of the 48 tumours treated, 35 were located in the facial and 
13 elsewhere. Practically all the lesions (47/48) resulted in a depth 
less than 3 mm. Local control at 3 months has been excellent (47/48) 
and registered a high dermal toxicity was grade 1 (RTOG/CTCAEv3), 
having being resolved with topical treatment at 4 weeks in all but one 
case that required 2 months. The esthetical result (RTOG/CTCAEv3) 
was magnificent in all cases. 
Conclusions: In our experience, the HDR-BT with Valencia Applicator 
in hypofractionated regime provides excellent results, for both 
cosmetic and local control in the short term, with little toxicity. 
Moreover the hypofractionation facilitates compliance with treatment 
comfort in elderly patients. 
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Purpose/Objective: To evaluate through Doppler ultrasound the 
intratumoral vascularization of uveal melanoma (UM) at diagnosis as a 
sign of tumoral activity, and to quantify its presence after treatment 
with brachytherapy. 
Materials and Methods: 50 cases of UM were treated with 
brachytherapy from July 2005 to June2010. 26 men and 24 women 
with an average age of 60. 70% melanotic, 18% amelanotic and 12% 
mixed. Location: 30% posterior, 16% postequatorial, 22% equatorial, 
20%peripheral and 12% in ciliary body. Mean basal size and apical 
thickness at diagnosis: 12.1 x 5.6 mm (SD 3.0-5.6). A 125-Iodine 
plaque was used in 70% of cases and 106-Ruthenium in 28%. 
Transpupillary thermotherapy (TTT) was associated in 10 cases. The 
apical dose was 85 Gy. Mean follow-up was of 29 months (13.7-69 
months). Duplex Doppler scans (gray scale and Doppler scans) were 
done at diagnosis and every 6months after treatment. Parameters 
evaluated: presence of intratumoral vessels, systolic peak velocity 
(SPV), end-diastolic velocity (EDV) and resistance index (RI= syst-
diast/syst). 
Results: Doppler detected intratumoral vascularization at diagnosis in 
21 of 50 cases (42%): vascularization persisted in 7 cases at 6, 12 and 
18 months. At 24 months only persisted 5/31, at 30 months 3/20, at 
36 months 1/12, at 42 months 1/6, at 48 months 1/3, at 54 months 
1/2 and at 60 months 0/1. Mean systolic peak velocity at diagnosis 
was 25.2±16.1 cm/s and 15.82±10.5 at 6 months. The treatment had 
asignificant impact on the detection of tumour vessels (p=0.035), 
controlled by age, sex, maximum tumoral diameter and tumoral 
thickness in a logistic regression model. Mean resistance index (RI) 
was lower in tumours before treatment (0.50 vs 0.59, p=0.0047). Out 
of 6 tumours with persistent signal during follow-up, 4 were in 
regression, 1 large tumour recurred and was enucleated, and another 
large one developed metastases. 8 avascular tumors at diagnosis 
experienced new vascularization during follow-up: 1 recurred and was 
enucleated and the other 7 showed ophthalmoscopic and echographic 
regression, and vascularization eventually disappeared. 4 of them 
developed neovascular glaucoma (NVG). Reduction of the apical 
thickness was more significant in initially vascularized tumors that had 
lost the Doppler signal than in tumors that remained avascular or 
vascular at 6months (p=0.365). The SPV dropped significantly at 6 
months (p=0,028) but EDVdid not (p=0.116). 
Conclusions: The non-invasive quantification of neovascular blood 
flow using pulsed Doppler for UM treated with brachytherapy offers a 
new diagnostic modality to evaluate the tumour activity. Most UM lose 
their Doppler signal in the first 6 months. Persistent intratumoral 
vascularization seems to relate to large tumours, recurrence or 
appearance of vascular congestion. The new vascularization cases can 
be explained by the persistence of old vessels, tumor recurrence or 
presence of NVG.  
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Purpose/Objective: Hilar cholangiocarcinoma (Klatskin tumours) are 
rare tumours with poor prognosis. The purpose of this work was to 
determine efficacy, toxicity, and patterns of recurrence in patients 
treated with endobiliary radiotherapy (RT) and external beam RT 
(EBRT) with chemotherapy. 
Materials and Methods: From Aug 2005 to July 2012, 65 patients with 
locally advanced non-metastatic hilar cholangiocarcinoma and were 
studied. All the patients presented with jaundice and required 
percutaneous biliary drainage. Endobiliary RT using HDR – Iridium 192 
(median dose 14 Gy/4# b.i.d), was delivered through the PTBD 
catheter which was followed by metal stenting. Twenty two (34%) 
patients received only endobiliary RT, while 27 (41%) patients after 
brachytherapy were further treated with concurr (median dose 
45Gy/25#). Sixteen (25%) patients in who were referred after metal 
stenting received Intensity modulated radiotherapy to a dose of 
57Gy/25# with concurrent Inj. Gemcitabine (300mg/mt2 weekly). 
Histopathological diagnosis was available in 50 patients (77%).  
Results: Median follow up for whole group was 7 months (range 1-31 
months). Twelve patients had complete response, 30 patients had 
partial response and 12 patients had stable disease, while 11 patients 
had locally progressive disease after radiation. Twenty one patients 
were alive at last follow up. The median overall survival (OAS) was 7 
months and one year OAS and Cancer specific survival (CSS) was 44% 
and 51% for whole group. Patients receiving endobiliary combined 
with chemoradiation or high dose chemoradiation alone had better 
survival as compared to patients receiving only endobiliary RT at 1 
year (55% vs.17%, p=0.001). The main sites of distant disease 
progression were liver and peritoneum. Thirty one patients (48%) 
developed cholangitis of which 8 patients succumbed to it. Four 
patients had late radiation toxicity, of these 3 had hematemesis due 
to duodenitis and one had radiation induced stricture at 
gastroesophageal junction requiring dilatation. 
Conclusions: These encouraging results suggest that endobiliary 
radiation in addition to chemoradiation is feasible with acceptable 
toxicity in unresectable Klatskin tumors and leads to better outcome 
as compared to those receiving only endobiliary RT alone. 
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Purpose/Objective: Keloids are challenging lesions to treat with high 
rates of recurrence. There are a multitude of treatment options 
available with various rates of success. Evidence has shown surgical 
resection followed by RT to have the highest level of local control and 
numerous reports have shown control rates of 65 – 90% with adjuvant 
external beam RT. Prior studies have demonstrated a spectrum of 
aggressiveness for keloids. Secondary keloids or lesions that have 
undergone prior resection and then recurred are often refractory to 
further treatment with higher rates of recurrence. Keloids that recur 
after combined surgery and EBRT are especially difficult cases and 
limited in therapy options. The objective of our study was to 
determine the efficacy of surgical resection of keloids followed by 
HDR brachytherapy for management of lesions at high risk for 
recurrence.  
Materials and Methods: This study is a retrospective analysis of 18 
patients representing 29 keloids found on various body sites including 
the chest wall, axilla, breast, ear, pelvis, chin, cheek, neck, back, 
shoulder, and abdomen, treated at Montefiore Medical Center 
between 1996 and 2011. Our study population consisted of mainly 
secondary lesions already treated in the past with the combination of 
surgery and EBRT, lesions treated with surgery alone, or primary 
keloids deemed to be at a high risk for recurrence due to their size 
and location. The treatment in this study consisted of complete 
surgical excision with placement of hollow brachytherapy catheters, 
immediately followed by HDR Iridium-192 brachytherapy to a total 
dose of 15Gy in 3 fractions, over 3 consecutive days, prescribed to a 
1cm depth. Endpoints assessed included recurrence rate, treatment 
complications, and side effects. 14 lesions had undergone prior 
resection(s) and external beam radiation, 6 had previously received 
surgery alone, and 9 were primary lesions. The two most common 
sites were earlobe and chest wall. The mean age at treatment was 43 
(range 23-64 years).  
Results: The mean follow up in our study was 62 months (range 12-192 
months). Analysis of the data demonstrated a recurrence-free rate of 
89.6% (26/29 lesions). Two of the recurrences had received previous 
surgery and EBRT and one was a primary keloid with no prior 
treatment. 7 patients experienced delayed wound healing but 
eventually had a full recovery. 3 patients had post-operative 
infections at the surgical site that were successfully treated. Two 
patients experienced mild intermittent parasthesias at the treatment 
site and one complained of mild pruritis post-treatment. For the other 
26 lesions, there was an improvement in keloid symptoms including 
pain, parasthesias, and pruritis. 
Conclusions: Surgical resection and adjuvant HDR Iridium-192 
brachytherapy provide excellent and enduring levels of local control 
for keloid lesions at high risk for recurrence and are well tolerated 
with acceptably minimal long term side effects with a mean follow up 
of 62 months.  
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Purpose/Objective: The aim of this study was to evaluate the 
feasibility, safety and the early clinical results of a new procedure of 
